Patents by Inventor Jacopo Millul

Jacopo Millul has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BIVALENT FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS
    Publication number: 20240148916
    Abstract: The present invention relates to ligands of Fibroblast Activation Protein (FAP) for the active delivery of various payloads (e.g. cytotoxic drugs, radionuclides, fluorophores, proteins and immunomodulators) at the site of disease. In particular, the present invention relates to the development of bivalent FAP ligands for targeting applications, in particular diagnostic methods and/or methods for therapy or surgery in relation to a disease or disorder, such as cancer, inflammation or another disease characterized by overexpression of FAP.
    Type: Application
    Filed: February 11, 2022
    Publication date: May 9, 2024
    Inventors: Samuele CAZZAMALLI, Andrea GALBIATI, Jacopo MILLUL, Aureliano ZANA
  • FIBROBLAST ACTIVATION PROTEIN (FAP) INHIBITORS, FAP CONJUGATES, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF
    Publication number: 20240131203
    Abstract: The present disclosure relates to the field of fibroblast activation protein (FAP) inhibitors, conjugates comprising the novel FAP inhibitors, including radiotracers, for the imaging, diagnosis and treatment of conditions characterized by overexpression of FAP.
    Type: Application
    Filed: September 25, 2023
    Publication date: April 25, 2024
    Applicants: Nuclidium AG, University of Basel
    Inventors: Leila JAAFAR-THIEL, Melpomeni FANI, Jacopo MILLUL, Francesco DE ROSE
  • FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS
    Publication number: 20230147962
    Abstract: The present invention relates to ligands of Fibroblast Activation Protein (FAP) for the active delivery of various payloads (e.g. cytotoxic drugs, radionuclides, fluorophores, proteins and immunomodulators) at the site of disease. In particular, the present invention relates to the development of FAP ligands for targeting applications, in particular diagnostic methods and/or methods for therapy or surgery in relation to a disease or disorder, such as cancer, inflammation or another disease characterized by overexpression of FAP.
    Type: Application
    Filed: February 12, 2021
    Publication date: May 11, 2023
    Inventors: Ilaria Biancofiore, Samuele Cazzamalli, Sheila Plaza Dakhel, Etienne J. Donckele, Jacopo Millul, Florent Samain, Eleonore Schmidt